L3VLUP
ProSign in

IOVA · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IOVAGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IOVA
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterIOVAGILD
Q3 20209 holders, $822m25 holders, $14.2bn
Q4 20209 holders, $1.8bn27 holders, $13.4bn
Q1 20218 holders, $1.2bn24 holders, $14.5bn
Q2 20216 holders, $917m18 holders, $14.9bn
Q3 20217 holders, $753m20 holders, $16.4bn
Q4 20218 holders, $517m20 holders, $16.8bn
Q1 20228 holders, $423m28 holders, $13.2bn
Q2 20227 holders, $121m26 holders, $13.6bn
Q3 20228 holders, $100m24 holders, $13.3bn
Q4 20226 holders, $43m32 holders, $21.1bn
Q1 20236 holders, $102m27 holders, $21.8bn
Q2 20234 holders, $102m24 holders, $20.7bn
Q3 20234 holders, $35m24 holders, $20.0bn
Q4 20237 holders, $105m22 holders, $21.5bn
Q1 20245 holders, $154m30 holders, $20.3bn
Q2 20244 holders, $98m28 holders, $18.5bn
Q3 20244 holders, $93m29 holders, $24.2bn
Q4 20243 holders, $52m28 holders, $25.9bn
Q1 20253 holders, $19m33 holders, $32.0bn
Q2 20251 holders, $45k27 holders, $30.9bn
Q3 20251 holders, $56k23 holders, $29.4bn
Q4 20251 holders, $71k25 holders, $34.3bn
Q1 20262 holders, $1.3m25 holders, $38.5bn
Q2 20261 holders, $79m26 holders, $34.2bn
IOVA

Iovance Biotherapeutics Inc

Holders
1
Reported value
$45k
Buyers
0
Sellers
1

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
27
Reported value
$30.9bn
Buyers
18
Sellers
10

Breadth +8 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2025

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only IOVA (1)

Farallon Capital Management LLC

Only GILD (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →